Literature DB >> 24418480

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

Pranabashis Haldar1, Christopher E Brightling1, Amisha Singapuri2, Beverley Hargadon2, Sumit Gupta1, William Monteiro2, Peter Bradding1, Ruth H Green2, Andrew J Wardlaw1, Hector Ortega3, Ian D Pavord4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24418480     DOI： 10.1016/j.jaci.2013.11.026

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  54 in total

Review 1.  Update on reslizumab for eosinophilic asthma.

Authors:  Juan Carlos Cardet; Elliot Israel
Journal:  Expert Opin Biol Ther       Date:  2015       Impact factor: 4.388

Review 2.  Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma.

Authors:  Leyla Pur Özyiğit; Ayşe Bilge Öztürk; Sevim Bavbek
Journal:  Turk Thorac J       Date:  2020-01-01

Review 3.  Biologic therapies targeting eosinophils: current status and future prospects.

Authors:  Fanny Legrand; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2015 Mar-Apr

Review 4.  Mepolizumab.

Authors: 
Journal:  Aust Prescr       Date:  2017-02-01

Review 5.  Biological Modulators in Eosinophilic Diseases.

Authors:  Panida Sriaroon; Mark Ballow
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

Review 6.  Asthma therapy and its effect on airway remodelling.

Authors:  Rachid Berair; Christopher E Brightling
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

Review 7.  Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.

Authors:  Christian Domingo
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

Review 8.  Biologic agents for severe asthma patients: clinical perspectives and implications.

Authors:  Massimo Caruso; Jaymin Morjaria; Rosalia Emma; Maria Domenica Amaradio; Riccardo Polosa
Journal:  Intern Emerg Med       Date:  2017-12-14       Impact factor: 3.397

Review 9.  Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.

Authors:  Matthew P Giannetti; Juan C Cardet
Journal:  Curr Allergy Asthma Rep       Date:  2016-11       Impact factor: 4.806

10.  Mepolizumab (Nucala) For Severe Eosinophilic Asthma.

Authors:  Min Sung Choy; Deepali Dixit; Mary Barna Bridgeman
Journal:  P T       Date:  2016-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.